CalciMedica’s (CALC) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report published on Thursday,Benzinga reports. They currently have a $16.00 price target on the stock.

CalciMedica Trading Down 1.2 %

Shares of CALC opened at $3.33 on Thursday. The firm’s fifty day simple moving average is $4.04 and its 200-day simple moving average is $4.53. The firm has a market capitalization of $35.80 million, a price-to-earnings ratio of -3.08 and a beta of 1.30. CalciMedica has a twelve month low of $2.68 and a twelve month high of $8.38.

Insider Transactions at CalciMedica

In related news, major shareholder Sanderling Venture Partners Vi acquired 86,867 shares of CalciMedica stock in a transaction dated Friday, November 1st. The stock was acquired at an average price of $3.75 per share, for a total transaction of $325,751.25. Following the transaction, the insider now owns 814,300 shares of the company’s stock, valued at $3,053,625. This represents a 11.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO A. Rachel Leheny bought 20,000 shares of the stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $3.75 per share, with a total value of $75,000.00. Following the acquisition, the chief executive officer now owns 130,926 shares in the company, valued at approximately $490,972.50. This represents a 18.03 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 312,944 shares of company stock valued at $1,172,910. 41.55% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Geode Capital Management LLC lifted its position in CalciMedica, Inc. (NASDAQ:CALC) by 51.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,553 shares of the company’s stock after purchasing an additional 22,525 shares during the quarter. Geode Capital Management LLC owned approximately 0.62% of CalciMedica worth $295,000 at the end of the most recent quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.